Lord, Abbett & Co
BOLD

Lord, Abbett & Co’s Audentes Therapeutics, Inc BOLD Stock Holding History

Lord, Abbett & Co’s Portfolio BOLD Stock Details BOLD Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2019
Q4 		– Sell
-669,112
Closed -$18.8M – 752
2019
Q3 		$18.8M Sell
669,112
-23,002
-3% -$785K 0.06% 419
2019
Q2 		$26.2M Buy
692,114
+34,983
+5% +$1.34M 0.09% 368
2019
Q1 		$25.6M Buy
657,131
+224,573
+52% +$6.44M 0.09% 363
2018
Q4 		$9.22M Sell
432,558
-501,201
-54% -$12.9M 0.03% 550
2018
Q3 		$37M Buy
933,759
+92,323
+11% +$3.44M 0.1% 334
2018
Q2 		$32.2M Buy
841,436
+508,690
+153% +$18.8M 0.09% 346
2018
Q1 		$10M Buy
332,746
+173,893
+109% +$5.89M 0.03% 621
2017
Q4 		$4.96M Buy
+158,853
New +$4.36M 0.01% 755

Other funds holding BOLD

BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
MF
Magnetar Financial Evanston, Illinois $9.84B AUM 190.64% 1-Year Est. Return
AAM
Alpine Associates Management Palm Beach, Florida $1.7B AUM 97.55% 1-Year Est. Return
AA
AQR Arbitrage Greenwich, Connecticut $6.09B AUM 27.01% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return
PHS
PFM Health Sciences San Francisco, California $1.1B AUM 57.92% 1-Year Est. Return
FCM
Farallon Capital Management San Francisco, California $17.5B AUM 50.95% 1-Year Est. Return
RCM
RA Capital Management Boston, Massachusetts $9.44B AUM 157.3% 1-Year Est. Return
CC
Casdin Capital New York $1.32B AUM 76.62% 1-Year Est. Return

Lord, Abbett & Co's BOLD Position: Q4 2019 in Review

Lord, Abbett & Co sold out of Audentes Therapeutics, Inc (BOLD) in Q4 2019, closing a stake of 669,112 shares — an estimated $18.8M sold.

Lord, Abbett & Co first reported a position in BOLD in Q4 2017 and held it in 8 quarters. The position peaked at $37M in Q3 2018. 188 funds tracked by Wall St. Rank hold BOLD as of Q4 2019.

  • Lord, Abbett & Co reported no remaining Audentes Therapeutics, Inc position as of Q4 2019 after selling out during the quarter.
  • Lord, Abbett & Co sold 669,112 Audentes Therapeutics, Inc shares in Q4 2019, an estimated $18.8M.
  • Lord, Abbett & Co first reported a position in Audentes Therapeutics, Inc in Q4 2017 and held it in 8 quarters.
  • Lord, Abbett & Co's Audentes Therapeutics, Inc position peaked at $37M in Q3 2018.
  • 188 funds tracked by Wall St. Rank held Audentes Therapeutics, Inc as of Q4 2019.

Based on Lord, Abbett & Co's 13F filing for Q4 2019, filed 14 Feb 2020.